Sivextro Gets FDA Approval for Adult Skin Infections — Physician’s First Watch
Sivextro Gets FDA Approval for Adult Skin Infections
By the Editors
A new antibacterial, tedizolid (marketed as Sivextro), has received FDA approval.
The agency says tedizolid is approved for use against acute bacterial skin and skin-structure infections in adults, including those caused by methicillin-resistant Staph. aureus, in addition to streptococci and enterococci. It's available in both intravenous and oral formulations.
In May the FDA approved another drug, dalbavancin (Dalvance), for the same indication.